trending Market Intelligence /marketintelligence/en/news-insights/trending/xe7p9tqvdl18mmavmsdzxq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

DBV Technologies to raise $150M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

DBV Technologies to raise $150M

DBV Technologies S.A. is looking to raise approximately $150 million via the sale of company shares.

The French biotechnology company is looking to sell 2,784,030 American depositary shares at $21.26 each in the U.S., Canada and certain non-European countries, and another 2,135,737 ordinary shares in Europe for €34.71 apiece.

Morgan Stanley and Goldman Sachs are acting as joint lead book-running managers for the global offering. Barclays and Deutsche Bank Securities are also serving as book-running managers.

Bryan Garnier & Co. is acting as a co-manager for the global offering.

The offering's underwriters will have an option to buy up to an additional 529,162 ordinary shares.

The company will use the proceeds to fund, among other things, the development and commercialization of its allergy treatment Viaskin Peanut.